Differences in cause and 12-month follow-up outcome of parkinsonian symptoms in depressed older adults treated with antipsychotics: a case series

Table 3 Brain imaging findings of older adults with depression and parkinsonian symptoms

Case No	Structural brain MR imaging		DaT scan*
	MTA-Scheltens Score**	White matter lesions/Fazekas Score***	Specific Binding Index right		Benamer’s criteria****
			Right	Left	Rater 1	Rater 2
1	2	1	2.17	2.10	0	0
2	1	2	2.05	2.12	1	1
3	1	0	2.04	2.03	0	0
4	No atrophy / Computerized tomography (CT) scan		2.03	2.02	0	1
5	2	1	2.02	2.06	0	0
6	No atrophy / Computerized tomography (CT) scan		2.00	1.88	2	3
7	2	1	1.85	2.07	1	1
8	2	Bilateral basal ganglia ischemic lesions/3	1.51	1.67	1	1

* iofluropane iodine-123 (DAT) single-photon emission computed tomography imaging (SPECT)
**Medial Temporal Lobe Atrophy (MTA) -Scheltens Score ranging from 0 (no atrophy) to 4 (severe atrophy)
***The 4-point Fazekas score is a whole brain scale: 0: No lesion or a single punctuate white matter lesion; 1: multiple punctuate lesions; 2: Beginning confluent lesions; 3: large confluent lesions
**** Benamer’s criteria: 0: preserved and largely symmetrical striatal tracer uptake; 1: asymmetric uptake with normal or almost normal putamen activity in one hemisphere, and with a more marked reduction in the contralateral putamen; 2: significant bilateral reduction in putamen uptake with activity confined to the caudate nuclei; 3: virtually absent uptake bilaterally affecting both putamen and caudate nuclei

ISSN: 1471-244X